Common reasons appeals succeed: The denial cited insufficient documentation, and the provider submits complete records showing all criteria were met The denial incorrectly stated the patient had not tried metformin, when pharmacy records show a 90-day trial The denial applied the wrong clinical criteria (e.g., requiring BMI 30 when the actual requirement is BMI 27 for diabetes patients) Common reasons appeals fail: The patient is requesting coverage for obesity without diabetes (no amount of documentation overcomes a formulary exclusion) The patient has not completed the required step therapy (metformin trial) The provider requested Wegovy instead of Ozempic for a diabetes patient (the appeal should request Ozempic instead) Step 3: Judicial review (within 30 days of Board of Hearings decision) If the Board of Hearings upholds the denial, you can file an appeal in Massachusetts Superior Court

Depending on the initial population density, the number of alive cells grows exponentially (top row - deterministic-growth phase) or decreases exponentially until extinction (bottom row - no-growth phase)
Investigational peptides: Some peptides have promising mechanisms or early studies but are not approved for routine clinical use
According to DSM-5-TR criteria, BED severity is classified as mild (1-3 episodes/week), moderate (4-7 episodes/week), or severe (8+ episodes/week), with each level requiring appropriate treatment intensity
This combination enhances its ability to stimulate cellular repair processes and promote collagen production
Case report(s)This section has been translated automatically